Simba Gill is CEO and president of moksha8, a leading Latin American pharmaceutical company focused on central nervous system disorders. He has a long track record of identifying new technologies and geographies for high-growth business opportunities. Moksha8 was founded in 2006 while Gill was an entrepreneur-in-residence at Texas Pacific Group (TPG). At moksha8, he founded a biosimilar antibody company called fourteen22. Prior to joining TPG, Gill was president of Maxygen, a pioneer in directed molecular evolution technologies for pharmaceutical, chemical and agricultural products. Before joining Maxygen, he led corporate development in the world's first stem cell company, Systemix. Previously he was global marketing director at Boehringer Mannheim. Gill began his career at Celltech, focused on antibody research. Fluent in five languages, he holds a Ph.D. from King's College, London, and an M.B.A. from INSEAD.

Panel:
Brazil: Making Growth Sustainable

Tweet